ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.00%. A quarter ago, it was expected that this company would post a loss of $0.2 per share when it actually produced a loss of $0.21, delivering a surprise of -5%.Over the last four quarters, the company has not ...

分组1 - Janux Therapeutics reported a quarterly loss of $0.39 per share, better than the Zacks Consensus Estimate of a loss of $0.60, and improved from a loss of $0.51 per share a year ago, resulting in an earnings surprise of +35.00% [1] - The company posted revenues of $10 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 28.01%, compared to revenues of $0.44 million in the same quarter last year [2] - Janux Therapeutics shares have declined approximately 48.6% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] 分组2 - The earnings outlook for Janux Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.74 on revenues of $1.25 million, and -$2.37 on revenues of $8.13 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Janux Therapeutics belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - TruBridge (TBRG) reported quarterly earnings of $0.88 per share, exceeding the Zacks Consensus Estimate of $0.4 per share, and showing a significant improvement from a loss of $0.21 per share a year ago, resulting in an earnings surprise of +120.00% [1] - The company achieved revenues of $86.11 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.32% and reflecting a year-over-year increase from $83.83 million [2] - TruBridge has outperformed consensus revenue estimates three times over the last four quarters [2] Earnings Outlook - The sustainability of TruBridge's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.46 on revenues of $88.61 million, and for the current fiscal year, it is $1.76 on revenues of $346.54 million [7] Industry Context - The Medical Info Systems industry, to which TruBridge belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - JFrog Ltd. reported quarterly earnings of $0.22 per share, exceeding the Zacks Consensus Estimate of $0.16 per share, and showing an increase from $0.15 per share a year ago, resulting in an earnings surprise of +37.50% [1] - The company achieved revenues of $136.91 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 6.63% and up from $109.06 million year-over-year [2] - JFrog shares have increased approximately 56.8% year-to-date, significantly outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The future performance of JFrog's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $131.57 million, and for the current fiscal year, it is $0.70 on revenues of $509.48 million [7] Industry Context - The Internet - Software industry, to which JFrog belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8]

分组1 - 10x Genomics reported a quarterly loss of $0.22 per share, better than the Zacks Consensus Estimate of a loss of $0.27, and an improvement from a loss of $0.30 per share a year ago, resulting in an earnings surprise of +18.52% [1] - The company achieved revenues of $149 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.64%, although this represents a decline from year-ago revenues of $151.65 million [2] - Over the last four quarters, 10x Genomics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] 分组2 - The stock has underperformed the market, losing about 6.1% since the beginning of the year, while the S&P 500 has gained 15.6% [3] - The company's earnings outlook is crucial for investors, with current consensus EPS estimates of -$0.23 for the coming quarter and -$0.52 for the current fiscal year, alongside revenues of $151.08 million and $620.66 million respectively [7] - The Medical Info Systems industry, to which 10x Genomics belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Core Viewpoint - Nerdy Inc. reported a quarterly loss of $0.1 per share, which was better than the Zacks Consensus Estimate of a loss of $0.16, indicating a positive earnings surprise of +37.50% [1] - The company’s revenues for the quarter were $37.02 million, missing the Zacks Consensus Estimate by 5.58% and down from $37.53 million a year ago [2] Financial Performance - Over the last four quarters, Nerdy has surpassed consensus EPS estimates four times and topped revenue estimates twice [2] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $59.31 million, and for the current fiscal year, it is -$0.34 on revenues of $191.39 million [7] Stock Performance - Nerdy shares have declined approximately 40.1% since the beginning of the year, contrasting with the S&P 500's gain of 15.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Schools industry, to which Nerdy belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Nerdy may also be influenced by the upcoming earnings report of KinderCare Learning Companies, Inc., another player in the same industry [9]

Financial Performance - PAR Technology reported quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share, compared to a loss of $0.09 per share a year ago, representing an earnings surprise of -33.33% [1] - The company posted revenues of $119.18 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.35%, and compared to year-ago revenues of $96.75 million [2] - Over the last four quarters, PAR Technology has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - PAR Technology shares have lost about 53.3% since the beginning of the year, while the S&P 500 has gained 15.6% [3] - The current status of estimate revisions translates into a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.13 on $113.6 million in revenues, and $0.24 on $439.8 million in revenues for the current fiscal year [7] - The outlook for the industry can materially impact the stock's performance, with the Financial Transaction Services industry currently in the bottom 38% of Zacks industries [8]

Core Insights - Eton Pharmaceuticals reported a quarterly loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.13, and showing a significant decline from earnings of $0.02 per share a year ago, resulting in an earnings surprise of -153.85% [1] - The company achieved revenues of $22.46 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 9.24%, and marking a substantial increase from $10.32 million in the same quarter last year [2] - Eton Pharmaceuticals has consistently surpassed consensus revenue estimates over the last four quarters, although it has not met EPS estimates during the same period [2] Future Outlook - The immediate price movement of Eton Pharmaceuticals' stock will largely depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $21.78 million, while for the current fiscal year, the estimate is $0.30 on revenues of $78.55 million [7] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future due to unfavorable estimate revisions prior to the earnings release [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Eton Pharmaceuticals belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable environment for stocks within this sector [8] - The performance of Eton Pharmaceuticals may also be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Block (XYZ) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -14.29%. A quarter ago, it was expected that this mobile payments services provider would post earnings of $0.6 per share when it actually produced earnings of $0.62, delivering a surprise of +3.33%.Over the last four quarter ...

Core Insights - Solventum (SOLV) reported quarterly earnings of $1.5 per share, exceeding the Zacks Consensus Estimate of $1.43 per share, but down from $1.64 per share a year ago, representing an earnings surprise of +4.90% [1] - The company achieved revenues of $2.1 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.33% and showing a slight increase from $2.08 billion year-over-year [2] - Solventum has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Earnings Outlook - The future performance of Solventum's stock will largely depend on management's commentary during the earnings call and the sustainability of its immediate price movement based on the latest earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.50 on revenues of $2.05 billion, while for the current fiscal year, the estimate is $5.95 on revenues of $8.29 billion [7] Industry Context - The Medical Services industry, to which Solventum belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5][6]